The capacity of short-chain fructo-oligosaccharides to stimulate faecal bifidobacteria: a dose-response relationship study in healthy humans

Yoram Bouhnik, Laurent Raskine, Guy Simoneau, Damien Paineau, Francis Bornet, Yoram Bouhnik, Laurent Raskine, Guy Simoneau, Damien Paineau, Francis Bornet

Abstract

Background: Short-chain fructo-oligosaccharides (scFOS) are well-known for their bifidogenicity. In a large study comprising 200 healthy volunteers, we determined the bifidogenic properties of 7 non-digestible carbohydrates administered at a dose of 10 g/d in the diet; we analysed dose-response relationships of the bifidogenic substrates at doses ranging from 2.5 to 10 g/d in comparison with a placebo. The aim of this presentation is to give more details about the dose-response effects of short-chain fructo-oligosaccharides (scFOS).

Methods: Forty healthy volunteers (18 males, 22 females) eating their usual diets were randomly divided into 5 groups of 8 subjects and received scFOS at a dose of 2.5, 5.0, 7.5 and 10 g/d or a placebo for 7 d. Stools were collected before (day (d) 8) and at the end (day (d) 15) of sugar consumption, and tolerance was evaluated using a daily chart. RESULTS (M +/- SEM): Bifidobacteria counts increase was higher in scFOS than in placebo group for all doses tested [2.5 g/d (from 9.15 +/- 0.59 to 9.39 +/- 0.70; P = 0.02); 5 g/d (from 10.21 +/- 0.21 to 10.67 +/- 0.22; P = 0.03); 7.5 g/d (from 9.28 +/- 0.49 to 9.85 +/- 0.35;P = 0.01); 10 g/d (from 9.00 +/- 0.81 to 10.18 +/- 0.60; P = 0.003)]. A significant correlation between the ingested dose of scFOS and faecal bifidobacteria counts was observed at d15 (r2 = 0.307, P < 0.001). Total anaerobes increased at the dose of 10 g/d. No significant differences were found for Bacteroides, Lactobacillus, enterobacteria or pH in any group. The frequency of digestive symptoms was not different between scFOS at any of the doses tested and placebo. Bloating was significantly more intense during scFOS ingestion at doses of 2.5 and 5 g/d, but not at doses of 7.5 and 10 g/d. Excess flatus, borborygmi and abdominal pain did not differ from the placebo at any of the doses tested.

Conclusion: This study showed that scFOS is bifidogenic and well tolerated at doses ranging from 2.5 to 10 g/d, and that there is a dose-response relationship in healthy volunteers.

Figures

Figure 1
Figure 1
Correlation between the dose of ingested scFOS and the faecal bifidobacteria counts on the d15 – d8 difference.

References

    1. Hirayama M, Sumi N, Hidaka H. Purification and properties of fructo-oligosaccharides producing beta-fructofuranosidase from Aspergillus niger ATCC 20611. Agric Biol Chem. 1989;53:667–673.
    1. Molis C, Flourie B, Ouarne F, Gailing MF, Lartigue S, Guibert A, Bornet F, Galmiche JP. Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. Am J Clin Nutr. 1996;64:324–328.
    1. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr. 1995;125:1401–1412.
    1. Buddington RK, Williams CH, Chen SC, Witherly SA. Dietary supplement of neosugar alters the fecal flora and decreases activities of some reductive enzymes in human subjects. Am J Clin Nutr. 1996;63:709–716.
    1. Bouhnik Y, Flourie B, Riottot M, Bisetti N, Gailing MF, Guibert A, Bornet F, Rambaud JC. Effects of fructo-oligosaccharides ingestion on fecal bifidobacteria and selected metabolic indexes of colon carcinogenesis in healthy humans. Nutr Cancer. 1996;26:21–29.
    1. Bullen CL, Willis AT. Resistance of the breast-fed infant to gastroenteritis. Br Med J. 1971;3:338–343.
    1. Bouhnik Y, Raskine L, Simoneau G, Vicaut E, Neut C, Flourié B, Brouns F, Bornet F. The capacity of nondigestible carbohydrates to stimulate fecal bifidobacteria in healthy humans: a double-blind, randomized, placebo-controlled, parallel-group, dose-response relation study. Am J Clin Nutr. 2004;6:1658–1664.
    1. Bouhnik Y, Vahedi K, Achour L, Attar A, Salfati J, Pochart P, Marteau P, Flourie B, Bornet F, Rambaud JC. Short-chain fructo-oligosaccharide administration dose-dependently increases fecal bifidobacteria in healthy humans. J Nutr. 1999;129:113–116.
    1. Rao AV. Dose-response effects of inulin and oligofructose on intestinal bifidogenesis effects. J Nutr. 1999;129:1442S–5S.
    1. Roberfroid MB, Van Loo JA, Gibson GR. The bifidogenic nature of chicory inulin and its hydrolysis products. J Nutr. 1998;128:11–19.
    1. Moro G, Minoli I, Mosca M, Fanaro S, Jelinek J, Stahl B, Boehm G. Dosage-related bifidogenic effects of galacto- and fructooligosaccharides in formula-fed term infants. J Pediatr Gastroenterol Nutr. 2002;34:291–295. doi: 10.1097/00005176-200203000-00014.
    1. Mitsuoka T, Hidaka H, Eida T. Effect of fructo-oligosaccharides on intestinal microflora. Nahrung. 1987;31:427–436.
    1. Samelson SL, Nelson RL, Nyhus LM. Protective role of faecal pH in experimental colon carcinogenesis. J R Soc Med. 1985;78:230–233.
    1. Malhotra SL. Faecal urobilinogen levels and pH of stools in population groups with different incidence of cancer of the colon, and their possible role in its aetiology. J R Soc Med. 1982;75:709–714.
    1. Hidaka H, Eida T, Takizawa T, Tokunaga T, Tashiro Y. Effects of fructo-oligosaccharides on intestinal flora and human health. Bifidobacteria Microflora. 1986;5:37–50.
    1. Evans DF, Pye G, Bramley R, Clark AG, Dyson TJ, Hardcastle JD. Measurement of gastrointestinal pH profiles in normal ambulant human subjects. Gut. 1988;29:1035–1041.
    1. Florent C, Flourie B, Leblond A, Rautureau M, Bernier JJ, Rambaud JC. Influence of chronic lactulose ingestion on the colonic metabolism of lactulose in man (an in vivo study) J Clin Invest. 1985;75:608–613.
    1. Gibson GR, Beatty ER, Wang X, Cummings JH. Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology. 1995;108:975–982. doi: 10.1016/0016-5085(95)90192-2.
    1. Rumessen JJ, Bode S, Hamberg O, Gudmand-Hoyer E. Fructans of Jerusalem artichokes: intestinal transport, absorption, fermentation, and influence on blood glucose, insulin, and C-peptide responses in healthy subjects. Am J Clin Nutr. 1990;52:675–681.
    1. Briet F, Achour L, Flourie B, Beaugerie L, Pellier P, Franchisseur C, Bornet F, Rambaud JC. Symptomatic response to varying levels of fructo-oligosaccharides consumed occasionally or regularly. Eur J Clin Nutr. 1995;49:501–507.
    1. Stone-Dorshow T, Levitt MD. Gaseous response to ingestion of a poorly absorbed fructo-oligosaccharide sweetener. Am J Clin Nutr. 1987;46:61–65.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться